Badania Rozwój Inwestycje Spółka z Ograniczoną Odpowiedzialnością (KRS 0000337174, NIP 7010199886) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. BADANIA ROZWÓJ INWESTYCJE operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since September 15, 2009. BADANIA ROZWÓJ INWESTYCJE's most recently reported net revenue was 0 PLN for 2021.
Historical suspension of activities
Suspension: August 16, 2022 - resumed: June 2, 2025
Bankruptcy proceedings
Bankruptcy proceedings are underway against the company.
Business profile - Badania Rozwój Inwestycje
Identity
- Name
- Badania Rozwój Inwestycje Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- September 15, 2009
- Registry status as of
- November 20, 2025
- Latest entry
- June 2, 2025
- Founding act
- 24.08.2009 R., NOTARIUSZ ILONA MARCHOCKA, JUSTYNA BASZUK, ILONA MARCHOCKA NOTARIUSZE - SPÓŁKA CYWILNA, 00-582 WARSZAWA, …
Articles of association history (2)
- August 24, 2009: 24.08.2009 R., NOTARIUSZ ILONA MARCHOCKA, JUSTYNA BASZUK, ILONA MARCHOCKA NOTARIUSZE - SPÓŁKA CYWILNA, 00-582 WARSZAWA, AL.SZUCHA 8, REPERTORIUM A NR 9280/2009
- February 16, 2016: AKTEM NOTARIALNYM Z DNIA 16.02.2016R., REP. NR 1115/2016 SPORZĄDZONYM PRZEZ NOTARIUSZA BARTŁOMIEJA JABŁOŃSKIEGO PROWADZĄCEGO KANCELARIĘ NOTARIALNĄ PRZY UL. ŻELAZNEJ 41 LOK. 8 ZMIENIONO § 2 I § 5 UST. 1 ORAZ W § 5 UST. 1 DODANO LITERY: O,P,Q,R,S,T,U,V,W W AKCIE ZAŁOŻYCIELSKIM SPÓŁKI
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
Address and contact
- Address
- UL. OBOZOWA, 60, 01-423, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.2298, 21.0117approx.
Risk and payment profile - Badania Rozwój Inwestycje
Credibility rating
51.6 / 100
Average credibility
Insolvency risk
Very low
Low threat
Closure risk
37
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
3
3/17 yrs
Board changes
4
4/17 yrs
PKD changes
2
2/17 yrs
Name changes
1
1/17 yrs
Data from 17 years of registry activity.
Credibility history
Payment reliability score from 2018–2021
Current: D (52/100)
Trend: deteriorating (-12.0 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2018–2021
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Badania Rozwój Inwestycje
Founded
September 15, 2009
16 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
5.0 K PLN
50 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
3 years
2018–2021 · profitable: 2/3
Registry entries
23
latest: June 2, 2025
Risk signals
Revenue
0 PLN
2021
Net profit
-100.0 K PLN
2021
Assets
5.1 M PLN
2021
Equity
859.5 K PLN
2021
EBITDA
N/A
2021
no depreciation data
Valuation
3.3 M PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Badania Rozwój Inwestycje.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
